Copaxone® 20mg/ml Is Preferred (DAW6) Over Its Generic

In order for the State to enhance the benefit of the PDL, in some instances the multisource brand name drug is Preferred over its generic equivalents, because the branded drug is less costly than its generic counterpart. This happens most often in cases of newly released generics. When manufacturer rebates are taken into consideration, the brand name drug has a lower net cost to the State.

Effective Monday, July 20, 2015, MMPP will cover brand Copaxone® 20mg/ml syringe over its generic counterpart (glatiramer acetate injection). Claims for Copaxone® 20mg/ml syringe must be submitted with DAW 6 and will be priced appropriately. Claims for Copaxone® 20mg/ml syringe with any other DAW code will reject. A DHMH Medwatch form will not be required.

- If any problems are encountered during the on-line claim adjudication of Preferred Brands, contact Xerox 24-hour Help Desk at 800-932-3918 for additional system overrides related to the use of the correct DAW code (for example, if there is other primary insurance). All Advisories are available online on DHMH’s web link at:
  http://mmcp.dhmh.maryland.gov/pap/SitePages/Provider%20Advisories.aspx